1st Quarter - Amendment

VENN STRATEGIES for REGENERON PHARMACEUTICALS, INC.

Firm
Client
Income
$60,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report Apr 19, 2016 $50,000 Replaced
1st Quarter - Amendment (this page) Jul 24, 2017 $60,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General issues relating to the bio-pharmaceutical sector, innovation, and health care manufacturing

LobbyistCovered position, as disclosed
TIM CAREY Legislative Director for U.S. Representative Brad Sherman (D-CA), Deputy Legislative Director for Representative Anna G. Eshoo (D-CA)
NATASCHA CUMBERLIDGE Rep. John Tierney (D-MA), where she most recently served as the Congressman's Senior Legislative Assistant
ELIZABETH LEE Senior Policy Advisor to the Administrator of the Health Resources and Services Administration, legislative aide to Senator Tammy Baldwin
DREW LITTMAN Chief of Staff to Senator Al Franken (D-MN)
STEPHANIE SILVERMAN —

Contacted: HOUSE OF REPRESENTATIVES; White House Office; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.